Literature DB >> 19050800

Transitional cell tumors of the ovary: a compact group with a heterogeneous histological and immunophenotypical pattern.

M Ceauşu1, Dana Terzea, Alina Georgescu, Camelia Dobrea, Mihaela Mihai, Cristina Iosif, Florina Vasilescu, Carmen Ardeleanu.   

Abstract

A small percentage of ovarian neoplasms are transitional cell tumors, which proves to be a distinct group with various histological and immunohistochemical patterns. In this study, 13 archived formalin-fixed paraffin-embedded samples of transitional cell tumors of the ovary have been assessed using standard HE stain and the indirect tristadial ABC peroxidase IHC method for 11 antibodies (CA125, CK7, CEA, EMA, MNF116, CK20, Vim, ER, PgR, PCNA, Ki-67). More than 50% were malignant Brenner tumors. CA125 was positive in all malignant tumors (of Brenner type and transitional cell carcinomas), but not in benign and borderline tumors, while CK7 was positive in approximately 70% of all cases. These two antibodies have shown a high sensitivity and low specificity, but do not correlate to each other. PCNA was positive in the study batch with a mean value of 40% and Ki-67 with a mean value under 25%. A direct correlation statistically significant has been noted between the aforementioned proliferation factors and the tumor grade (r = 0.4, p = 0.05). The other markers were unspecific, with low sensitivity and independently of the histopathological type.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19050800

Source DB:  PubMed          Journal:  Rom J Morphol Embryol        ISSN: 1220-0522            Impact factor:   1.033


  2 in total

1.  Good survival in a patient with recurrent transitional cell carcinoma of the ovary: A case report of PET-CT for detection and follow-up.

Authors:  Jingquan Ma; Lijuan Yu; Xinghua Wang; G E Lou
Journal:  Oncol Lett       Date:  2015-05-20       Impact factor: 2.967

2.  Transitional cell carcinoma of the ovary (Review).

Authors:  Satoshi Ichigo; Hiroshi Takagi; Kazutoshi Matsunami; Takayuki Murase; Tsuneko Ikeda; Atsushi Imai
Journal:  Oncol Lett       Date:  2011-10-21       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.